Literature DB >> 34324403

Longitudinal Experience With and Impressions of COVID-19-Related Clinical Research Changes.

David E Gerber1,2,3, Valerie L Clark2, Thomas Y Sheffield3, M Shaalan Beg1,2, Yang Xie2,3, M E Blair Holbein3, Celette Sugg Skinner2,3, Simon J Craddock Lee2,3, Erin L Williams2.   

Abstract

PURPOSE: The COVID-19 pandemic has led to profound changes in clinical research, including remote consent, telehealth, off-site procedures, shipment of therapy, and remote study monitoring. We assessed longitudinal perceptions of these adjustments among clinical research professionals.
METHODS: We distributed an anonymous survey assessing experiences, perceptions, and recommendations regarding COVID-19-related clinical research adjustments to cancer clinical research office personnel in May 2020 and again in November 2020. Responses were compared using Fisher's exact and Mann-Whitney U tests.
RESULTS: A total of 90 of 102 invited research personnel (88%) responded. Fifty-three (59%) reported participating in both initial and follow-up surveys. The proportion of respondents reporting personal experience with COVID-19-related adjustments increased over time, particularly for remote initial consent (29% v 4%), remote reconsent (24% v 9%), and remote study monitoring (36% v 22%). Perceived impact of COVID-19-related adjustments on data quality (P = .02) and patient experience (P = .002) improved significantly. However, perceived effect on patient safety (P = .02) and respondent's experience (P = .09) became less favorable. Individuals with personal experience with the adjustment were more likely to recommend continuing remote consent (62% v 38%; P = .04), remote monitoring (69% v 45%; P = .05), and therapy shipment (67% v 35%; P = .01) after the COVID-19 pandemic, with nonsignificant trends for off-site diagnostics (44% v 24%; P = .13) and telehealth visits (66% v 45%; P = .08).
CONCLUSION: More than 6 months into the global pandemic, perceptions of COVID-19-related clinical research changes remain favorable. Experienced individuals are more likely to recommend that these changes continue in the future.

Entities:  

Mesh:

Year:  2021        PMID: 34324403      PMCID: PMC8757963          DOI: 10.1200/OP.21.00169

Source DB:  PubMed          Journal:  JCO Oncol Pract        ISSN: 2688-1527


  18 in total

1.  Should criteria for inclusion in cancer clinical trials be expanded?

Authors:  David E Gerber; Sandi L Pruitt; Ethan A Halm
Journal:  J Comp Eff Res       Date:  2015-08       Impact factor: 1.744

2.  A study in contrasts: eligibility criteria in a twenty-year sample of NSABP and POG clinical trials. National Surgical Adjuvant Breast and Bowel Program. Pediatric Oncology Group.

Authors:  A Fuks; C Weijer; B Freedman; S Shapiro; M Skrutkowska; A Riaz
Journal:  J Clin Epidemiol       Date:  1998-02       Impact factor: 6.437

3.  Pandemic fatigue? How adherence to covid-19 regulations has been misrepresented and why it matters.

Authors:  Stephen Reicher; John Drury
Journal:  BMJ       Date:  2021-01-18

4.  Transforming Clinical Trial Eligibility Criteria to Reflect Practical Clinical Application.

Authors:  Edward S Kim; Jennifer Atlas; Gwynn Ison; Jennifer L Ersek
Journal:  Am Soc Clin Oncol Educ Book       Date:  2016

5.  Thoracic Oncology Clinical Trial Eligibility Criteria and Requirements Continue to Increase in Number and Complexity.

Authors:  Sandra Garcia; Ajit Bisen; Jingsheng Yan; Xian-Jin Xie; Suresh Ramalingam; Joan H Schiller; David H Johnson; David E Gerber
Journal:  J Thorac Oncol       Date:  2017-08-09       Impact factor: 15.609

6.  Resolving Rivalries and Realigning Goals: Challenges of Clinical and Research Multiteam Systems.

Authors:  David E Gerber; Torsten Reimer; Erin L Williams; Mary Gill; Laurin Loudat Priddy; Deidi Bergestuen; Joan H Schiller; Haskell Kirkpatrick; Simon J Craddock Lee
Journal:  J Oncol Pract       Date:  2016-09-30       Impact factor: 3.840

7.  Supporting the Health Care Workforce During the COVID-19 Global Epidemic.

Authors:  James G Adams; Ron M Walls
Journal:  JAMA       Date:  2020-04-21       Impact factor: 56.272

8.  Early Impact of COVID-19 on the Conduct of Oncology Clinical Trials and Long-Term Opportunities for Transformation: Findings From an American Society of Clinical Oncology Survey.

Authors:  David M Waterhouse; R Donald Harvey; Patricia Hurley; Laura A Levit; Edward S Kim; Heidi D Klepin; Kathryn Finch Mileham; Grzegorz Nowakowski; Caroline Schenkel; Courtney Davis; Suanna S Bruinooge; Richard L Schilsky
Journal:  JCO Oncol Pract       Date:  2020-05-12

9.  Cancer Center Clinic and Research Team Perceptions of Identity and Interactions.

Authors:  Torsten Reimer; Simon J Craddock Lee; Sandra Garcia; Mary Gill; Tobi Duncan; Erin L Williams; David E Gerber
Journal:  J Oncol Pract       Date:  2017-10-13       Impact factor: 3.840

10.  Rethinking cancer clinical trials for COVID-19 and beyond.

Authors:  Mehmet Goksu; Bruno H R de Paula; Gary J Doherty
Journal:  Nat Cancer       Date:  2020-05-29
View more
  1 in total

1.  Participant and research team perspectives on the conduct of a remote therapeutic COVID-19 clinical trial: A mixed methods approach.

Authors:  Denise H Daudelin; Sarah K Brewer; Alyssa B Cabrera; Dorothy Dulko; Harry P Selker
Journal:  J Clin Transl Sci       Date:  2022-05-02
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.